Program 2021
Time | Speaker | Topic |
13:00 | Prof. Dr. Holger Gohlke Insitute of Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf | Welcome and Introduction |
13:10 – 14:00 | Dr. Simone Moser Department of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of Munich | Phyllobilins - Chlorophyll breakdown as source of bioactive compounds |
14:00 – 14:30 | Marco Kruppa Insitute of Organic Chemistry, Heinrich-Heine-University Düsseldorf | Diversity-oriented synthesis of symmetrically and unsymmetrically substituted Alocasin A derivatives against therapy resistant bacteria |
14:30 – 15:00 | Laura Schmitt Institute of Molecular Biology I, Heinrich-Heine-University, Düsseldorf | The impact of novel meriolin derivatives on apoptosis and cell cycle progression in leukemia cells |
15:00 – 15:15 | Short Break | |
15:15 – 15:55 | Dr. Susanne Roehrig Bayer AG Pharmaceuticals | Discovery and development of the novel antithrombotic agent rivaroxaban, an orally active, direct factor Xa inhibitor |
15:55 – 16:45 | Prof. Dr. Anna K. H. Hirsch Department of Drug Design and Optimization, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research & Department of Pharmacy, Saarland University, 66123 Saarbrücken, Germany | Addressing unusual anti-infective targets |
16:45 – 17:00 | Short Break | |
17:00 – 17:50 | Prof. Dr. Jon Clardy Blavatnik Institute, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard University, Boston, USA | Chasing molecules and mechanisms in the human gut microbiome |
18:00 | Holger Gohlke | Closing Remarks |